1000 Mylan Boulevard
Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, Mylan innovates to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership
Founders: Milan Puskar, and Don Panoz
CEO: Heather Bresch
CFO: Neil Dimick
988 articles with Mylan
While there is no cure for the disease, there are a number of drugs that have been approved to treat the illness. And with the growing number of cases, the drug market for COPD is expected to dramatically increase as well.
The letter outlines multiple failures, including failure to have adequate written procedures for the receipt, identification and handling of raw materials and failure to adequately clean equipment and utensils.
Mylan N.V. and Pfizer Inc. announced that the name of the new company to be formed by the planned combination of Mylan and Upjohn, a division of Pfizer, will be Viatris.
Mylan N.V. announced its financial results for the three and nine months ended September 30, 2019.
The batch being recalled has the lot number 8082708. Medication from this lot was sold between July and August of this year, the company said.
Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will release its third quarter 2019 financial results on Tuesday, Nov. 5 before the open of the U.S. financial markets.
Mylan N.V. announced that it has finalized a previously disclosed civil settlement with the U.S. Securities and Exchange Commission.
Aiming to Expand Availability of Eribulin to Patients in India with Two Brands Halaven and Teceris
Entered into a license agreement to promote and distribute the second brand TECERIS for the anticancer agent eribulin mesylate (eribulin) in India.
Mylan Expands Oncology Portfolio with Launch of Generic Faslodex® Injection, a Treatment for Advanced Breast Cancer
Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product, which is used to treat certain types of advanced breast cancer in women who have experienced menopause as monotherapy and in advanced or metastatic breast cancer in combination with other products.
The U.S. Food and Drug Administration (FDA) gave tentative approval to Mylan’s pemetrexed, a generic version of Eli Lilly’s $2 billion lung cancer drug, Alimta.
Novo Nordisk filed a lawsuit in a Delaware district court against generic drugmaker Mylan. The suit is an attempt to block Mylan from marketing a generic version of Novo Nordisk’s diabetes drug Victoza.
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Mylan N.V. in connection with the proposed acquisition of the Company by Pfizer Inc..
Pfizer Inc. Reschedules Second-Quarter 2019 Earnings Conference Call to July 29, 2019 at 10:30 a.m. EDT
Pfizer’s second-quarter 2019 earnings conference call with investment analysts has been rescheduled for, July 29, 2019, at 10:30 a.m. EDT.
Statement from Mylan's Board of Directors Regarding Retirement of CEO and Board Member Heather Bresch in Conjunction with the Combination of Mylan and Upjohn, a Division of Pfizer
Mylan's Board of Directors shared the following statement regarding Heather Bresch's retirement, which will be effective upon the closing of the combination of Mylan and Upjohn, a division of Pfizer.
Mylan and Upjohn, a Division of Pfizer, to Combine, Creating a New Champion for Global Health Uniquely Positioned to Fulfill the World’s Need for Medicine
Combines Mylan’s sustainable, diverse and differentiated portfolio of medicines with Upjohn’s trusted, iconic brands
Mylan and Upjohn, a Division of Pfizer, to Combine, Creating a New Champion for Global Health Uniquely Positioned to Fulfill the World's Need for Medicine
Mylan N.V. and Pfizer Inc. announced a definitive agreement to combine Mylan with Upjohn, Pfizer's off-patent branded and generic established medicines business, creating a new global pharmaceutical company.
Mylan N.V. announced its financial results for the three and six months ended June 30, 2019.
7/29/2019The new company will be helmed by Mylan's Michael Goettler and is expected to generate 2020 revenues of $19 to $20 billion.
Theravance Biopharma and Mylan Expand YUPELRI® (revefenacin) Development and Commercialization Agreement to Include China and Adjacent Territories - June 14, 2019
First and only once-daily, nebulized bronchodilator has potential to address unmet needs of China's nearly 100 million chronic obstructive pulmonary disease (COPD) patients [14-June-2019] DUBLIN and HERTFORDSHIRE, England and PITTSBURGH , June 14, 2019 /PRNewswire/ -- Theravance Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, Inc. (NASDAQ: TBPH) (